Welch Group LLC acquired a new position in Amgen, Inc. (NASDAQ:AMGN) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 852 shares of the medical research company’s stock, valued at approximately $148,000.
Several other institutional investors have also recently modified their holdings of AMGN. Janus Henderson Group PLC grew its position in Amgen by 3,664.7% during the 2nd quarter. Janus Henderson Group PLC now owns 3,699,351 shares of the medical research company’s stock worth $637,139,000 after purchasing an additional 3,601,087 shares during the last quarter. FMR LLC lifted its stake in Amgen by 4.8% during the 2nd quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock valued at $9,817,037,000 after acquiring an additional 2,587,041 shares during the period. Renaissance Technologies LLC lifted its stake in Amgen by 40.9% during the 2nd quarter. Renaissance Technologies LLC now owns 3,400,145 shares of the medical research company’s stock valued at $585,607,000 after acquiring an additional 986,700 shares during the period. BlackRock Inc. lifted its stake in Amgen by 1.9% during the 2nd quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock valued at $8,516,980,000 after acquiring an additional 909,689 shares during the period. Finally, Nordea Investment Management AB lifted its stake in Amgen by 12.9% during the 2nd quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock valued at $1,212,602,000 after acquiring an additional 806,119 shares during the period. 79.53% of the stock is currently owned by hedge funds and other institutional investors.
AMGN opened at $168.14 on Friday. The company has a quick ratio of 5.17, a current ratio of 5.49 and a debt-to-equity ratio of 1.35. Amgen, Inc. has a 1 year low of $152.16 and a 1 year high of $201.23. The firm has a market capitalization of $125,031.95, a P/E ratio of 13.37, a PEG ratio of 2.13 and a beta of 1.36.
Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.84 billion. During the same quarter in the prior year, the firm earned $2.89 earnings per share. The business’s revenue for the quarter was down 2.7% on a year-over-year basis. equities research analysts forecast that Amgen, Inc. will post 13.25 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 8th. Shareholders of record on Thursday, May 17th will be given a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a yield of 3.14%. The ex-dividend date is Wednesday, May 16th. Amgen’s dividend payout ratio is presently 41.97%.
Amgen declared that its board has authorized a share buyback program on Thursday, February 1st that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the medical research company to purchase shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its stock is undervalued.
Several analysts have commented on the stock. Barclays decreased their price objective on shares of Amgen from $190.00 to $180.00 and set an “equal weight” rating for the company in a research note on Thursday. Zacks Investment Research upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $194.00 price objective for the company in a research note on Thursday. ValuEngine cut shares of Amgen from a “buy” rating to a “hold” rating in a research note on Monday, April 2nd. BidaskClub cut shares of Amgen from a “hold” rating to a “sell” rating in a research note on Saturday, March 24th. Finally, Vetr cut shares of Amgen from a “hold” rating to a “sell” rating and set a $181.60 price objective for the company. in a research note on Tuesday, March 6th. Two equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating and eleven have assigned a buy rating to the company. Amgen presently has a consensus rating of “Hold” and an average target price of $190.57.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction on Wednesday, February 14th. The shares were sold at an average price of $174.18, for a total transaction of $265,624.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 4,575 shares of company stock valued at $838,064 over the last 90 days. 0.19% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: This piece was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/07/852-shares-in-amgen-inc-amgn-purchased-by-welch-group-llc.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.